IDXX Idexx Laboratories

Q1 2025 10-Q

Filed: May 1, 2025Period ending Mar 31, 2025

Health Care

In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR

Idexx Laboratories (IDXX) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 1, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Management Discussion & Analysis

• No quarterly revenue or YoY change details disclosed
• No profitability or margin figures provided

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$998M

▲ +3.6% YoY

Net Income

$243M

▲ +3.0% YoY

Gross Margin

62.4%

▲ +92bp YoY

Operating Margin

31.7%

▲ +69bp YoY

Net Margin

24.3%

▼ -13bp YoY

EPS (Diluted)

$2.96

▲ +5.3% YoY

Operating Cash Flow

$238M

▲ +19.8% YoY

Source: XBRL data from Idexx Laboratories Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Idexx Laboratories Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Idexx Laboratories

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.